Infection News

Metabolic comorbidities heightened risk for adverse liver-related events among patients with chronic hepatitis B virus, with the highest risk found among patients with multiple comorbidities, according to research.

More than 40% of healthy mothers recruited for a study testing fecal transplantation for babies born by cesarean section tested positive for potentially harmful pathogens, Finnish researchers reported.

Infection with SARS-CoV-2 increased the risk for long-term gastrointestinal problems within 1 year, including motility disorders, acute pancreatitis and liver disease, according to a study published in Nature Communications.

Meridian Bioscience has announced FDA 510(k) clearance of its Curian Shiga Toxin assay intended for detection and differentiation of Shiga toxin 1 and 2 within a single device, according to a company release.

Although Black individuals with chronic hepatitis B were less likely to meet treatment criteria, researchers reported no significant differences in treatment initiation between racial groups, according to data in JAMA Network Open.

Results from a systematic review and meta-analysis demonstrated greater risk for hepatitis C virus and HIV infection among women and younger people who inject drugs, according to data reported in The Lancet Gastroenterology & Hepatology.

Hospitalized patients with COVID-19 had a “modest increased risk” for long-term gastrointestinal symptoms and irritable bowel syndrome compared with control patients, according to research published in Gut.

The eradication rate of Helicobacter pylori in Africa varied widely by country, duration of therapy and type of diagnostic test used, underscoring the need for optimized treatment regimens, according to a systemic review and meta-analysis.

Individuals with certain germline pathogenic variants had a substantially higher risk for developing gastric cancer after Helicobacter pylori infection, results of a Japan-based case-control study showed.

Use of the investigational microbiome therapeutic SER-109 resulted in rapid and steady improvement in disease-specific quality of life for patients with recurrent Clostridioides difficile infection, according to data in JAMA Network Open.